Shingles Vaccine Market By Vaccine Type (Recombinant Shingles Vaccine, Live Attenuated Shingles Vaccine), By Vaccine Composition (Monovalent Vaccines, Combination Vaccines), By Immunization Type (Preventive Vaccination, Therapeutic Vaccination), By Route of Administration (Intramuscular (IM), Subcutaneous (SC)), and By End User (Hospitals, Specialty Clinics, Vaccination Centers, Homecare Settings), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & Forecast Parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Shingles Vaccine Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. How does increasing elderly population boost shingles vaccine demand?

3.2.2. Can rising awareness about shingles complications drive vaccine adoption?

3.2.3. Does government immunization support enhance shingles vaccine market growth?

3.3. Key industry pitfalls & challenges

3.3.1. What impact does high vaccine cost have on patient access?

3.3.2. Could limited healthcare infrastructure restrict shingles vaccine distribution?

3.3.3. Are vaccine side effects causing hesitation among potential recipients?

3.4. Market Opportunities

3.4.1. How might developing countries expand shingles vaccine penetration soon?

3.4.2. Can innovative vaccine formulations improve efficacy and acceptance rates?

3.4.3. Will partnerships with healthcare providers accelerate vaccination programs worldwide?

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Shingles Vaccine Market, Vaccine Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Vaccine Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Recombinant Shingles Vaccine

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Live Attenuated Shingles Vaccine

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Shingles Vaccine Market, Vaccine Composition Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Vaccine Composition, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Monovalent Vaccines

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Combination Vaccines

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Shingles Vaccine Market, Immunization Type Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Immunization Type, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Preventive Vaccination

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Therapeutic Vaccination

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Shingles Vaccine Market, Route of Administration Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By Route of Administration, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Intramuscular (IM)

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Subcutaneous (SC)

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Shingles Vaccine Market, End-user Segment Analysis

8.1. Overview

8.1.1. Market Revenue Share, By End-user, 2025 & 2035

8.1.2. Key Market Trends, Growth Factors, & Opportunities

8.2. Hospitals

8.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.3. Specialty Clinics

8.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.4. Vaccination Centers

8.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.5. Homecare Settings

8.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

9. Shingles Vaccine Market, Region Segment Analysis

9.1. Overview

9.1.1. Global Market Revenue Share, By Region, 2025 & 2035

9.1.2. Global Market Revenue, By Region, 2025-2035 (USD Billion)

9.2. North America

9.2.1. North America Market Revenue, By Country, 2025-2035 (USD Billion)

9.2.2. North America Market Revenue, By Vaccine Type, 2025-2035

9.2.3. North America Market Revenue, By Vaccine Composition, 2025-2035

9.2.4. North America Market Revenue, By Immunization Type, 2025-2035

9.2.5. North America Market Revenue, By Route of Administration, 2025-2035

9.2.6. North America Market Revenue, By End-user, 2025-2035

9.2.7. The U.S.

9.2.7.1. U.S. Market Revenue, By Vaccine Type, 2025-2035

9.2.7.2. U.S. Market Revenue, By Vaccine Composition, 2025-2035

9.2.7.3. U.S. Market Revenue, By Immunization Type, 2025-2035

9.2.7.4. U.S. Market Revenue, By Route of Administration, 2025-2035

9.2.7.5. U.S. Market Revenue, By End-user, 2025-2035

9.2.8. Canada

9.2.8.1. Canada Market Revenue, By Vaccine Type, 2025-2035

9.2.8.2. Canada Market Revenue, By Vaccine Composition, 2025-2035

9.2.8.3. Canada Market Revenue, By Immunization Type, 2025-2035

9.2.8.4. Canada Market Revenue, By Route of Administration, 2025-2035

9.2.8.5. Canada Market Revenue, By End-user, 2025-2035

9.3. Europe

9.3.1. Europe Market Revenue, By Country, 2025-2035 (USD Billion)

9.3.2. Europe Market Revenue, By Vaccine Type, 2025-2035

9.3.3. Europe Market Revenue, By Vaccine Composition, 2025-2035

9.3.4. Europe Market Revenue, By Immunization Type, 2025-2035

9.3.5. Europe Market Revenue, By Route of Administration, 2025-2035

9.3.6. Europe Market Revenue, By End-user, 2025-2035

9.3.7. Germany

9.3.7.1. Germany Market Revenue, By Vaccine Type, 2025-2035

9.3.7.2. Germany Market Revenue, By Vaccine Composition, 2025-2035

9.3.7.3. Germany Market Revenue, By Immunization Type, 2025-2035

9.3.7.4. Germany Market Revenue, By Route of Administration, 2025-2035

9.3.7.5. Germany Market Revenue, By End-user, 2025-2035

9.3.8. France

9.3.8.1. France Market Revenue, By Vaccine Type, 2025-2035

9.3.8.2. France Market Revenue, By Vaccine Composition, 2025-2035

9.3.8.3. France Market Revenue, By Immunization Type, 2025-2035

9.3.8.4. France Market Revenue, By Route of Administration, 2025-2035

9.3.8.5. France Market Revenue, By End-user, 2025-2035

9.3.9. U.K.

9.3.9.1. U.K. Market Revenue, By Vaccine Type, 2025-2035

9.3.9.2. U.K. Market Revenue, By Vaccine Composition, 2025-2035

9.3.9.3. U.K. Market Revenue, By Immunization Type, 2025-2035

9.3.9.4. U.K. Market Revenue, By Route of Administration, 2025-2035

9.3.9.5. U.K. Market Revenue, By End-user, 2025-2035

9.3.10. Italy

9.3.10.1. Italy Market Revenue, By Vaccine Type, 2025-2035

9.3.10.2. Italy Market Revenue, By Vaccine Composition, 2025-2035

9.3.10.3. Italy Market Revenue, By Immunization Type, 2025-2035

9.3.10.4. Italy Market Revenue, By Route of Administration, 2025-2035

9.3.10.5. Italy Market Revenue, By End-user, 2025-2035

9.3.11. Spain

9.3.11.1. Spain Market Revenue, By Vaccine Type, 2025-2035

9.3.11.2. Spain Market Revenue, By Vaccine Composition, 2025-2035

9.3.11.3. Spain Market Revenue, By Immunization Type, 2025-2035

9.3.11.4. Spain Market Revenue, By Route of Administration, 2025-2035

9.3.11.5. Spain Market Revenue, By End-user, 2025-2035

9.3.12. Rest of Europe

9.3.12.1. Rest of Europe Market Revenue, By Vaccine Type, 2025-2035

9.3.12.2. Rest of Europe Market Revenue, By Vaccine Composition, 2025-2035

9.3.12.3. Rest of Europe Market Revenue, By Immunization Type, 2025-2035

9.3.12.4. Rest of Europe Market Revenue, By Route of Administration, 2025-2035

9.3.12.5. Rest of Europe Market Revenue, By End-user, 2025-2035

9.4. Asia Pacific

9.4.1. Asia Pacific Market Revenue, By Country, 2025-2035 (USD Billion)

9.4.2. Asia Pacific Market Revenue, By Vaccine Type, 2025-2035

9.4.3. Asia Pacific Market Revenue, By Vaccine Composition, 2025-2035

9.4.4. Asia Pacific Market Revenue, By Immunization Type, 2025-2035

9.4.5. Asia Pacific Market Revenue, By Route of Administration, 2025-2035

9.4.6. Asia Pacific Market Revenue, By End-user, 2025-2035

9.4.7. China

9.4.7.1. China Market Revenue, By Vaccine Type, 2025-2035

9.4.7.2. China Market Revenue, By Vaccine Composition, 2025-2035

9.4.7.3. China Market Revenue, By Immunization Type, 2025-2035

9.4.7.4. China Market Revenue, By Route of Administration, 2025-2035

9.4.7.5. China Market Revenue, By End-user, 2025-2035

9.4.8. Japan

9.4.8.1. Japan Market Revenue, By Vaccine Type, 2025-2035

9.4.8.2. Japan Market Revenue, By Vaccine Composition, 2025-2035

9.4.8.3. Japan Market Revenue, By Immunization Type, 2025-2035

9.4.8.4. Japan Market Revenue, By Route of Administration, 2025-2035

9.4.8.5. Japan Market Revenue, By End-user, 2025-2035

9.4.9. India

9.4.9.1. India Market Revenue, By Vaccine Type, 2025-2035

9.4.9.2. India Market Revenue, By Vaccine Composition, 2025-2035

9.4.9.3. India Market Revenue, By Immunization Type, 2025-2035

9.4.9.4. India Market Revenue, By Route of Administration, 2025-2035

9.4.9.5. India Market Revenue, By End-user, 2025-2035

9.4.10. Australia

9.4.10.1. Australia Market Revenue, By Vaccine Type, 2025-2035

9.4.10.2. Australia Market Revenue, By Vaccine Composition, 2025-2035

9.4.10.3. Australia Market Revenue, By Immunization Type, 2025-2035

9.4.10.4. Australia Market Revenue, By Route of Administration, 2025-2035

9.4.10.5. Australia Market Revenue, By End-user, 2025-2035

9.4.11. South Korea

9.4.11.1. South Korea Market Revenue, By Vaccine Type, 2025-2035

9.4.11.2. South Korea Market Revenue, By Vaccine Composition, 2025-2035

9.4.11.3. South Korea Market Revenue, By Immunization Type, 2025-2035

9.4.11.4. South Korea Market Revenue, By Route of Administration, 2025-2035

9.4.11.5. South Korea Market Revenue, By End-user, 2025-2035

9.4.12. Singapore

9.4.12.1. Singapore Market Revenue, By Vaccine Type, 2025-2035

9.4.12.2. Singapore Market Revenue, By Vaccine Composition, 2025-2035

9.4.12.3. Singapore Market Revenue, By Immunization Type, 2025-2035

9.4.12.4. Singapore Market Revenue, By Route of Administration, 2025-2035

9.4.12.5. Singapore Market Revenue, By End-user, 2025-2035

9.4.13. Rest of Asia Pacific

9.4.13.1. Rest of Asia Pacific Market Revenue, By Vaccine Type, 2025-2035

9.4.13.2. Rest of Asia Pacific Market Revenue, By Vaccine Composition, 2025-2035

9.4.13.3. Rest of Asia Pacific Market Revenue, By Immunization Type, 2025-2035

9.4.13.4. Rest of Asia Pacific Market Revenue, By Route of Administration, 2025-2035

9.4.13.5. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035

9.5. Latin America

9.5.1. Latin America Market Revenue, By Country, 2025-2035 (USD Billion)

9.5.2. Latin America Market Revenue, By Vaccine Type, 2025-2035

9.5.3. Latin America Market Revenue, By Vaccine Composition, 2025-2035

9.5.4. Latin America Market Revenue, By Immunization Type, 2025-2035

9.5.5. Latin America Market Revenue, By Route of Administration, 2025-2035

9.5.6. Latin America Market Revenue, By End-user, 2025-2035

9.5.7. Brazil

9.5.7.1. Brazil Market Revenue, By Vaccine Type, 2025-2035

9.5.7.2. Brazil Market Revenue, By Vaccine Composition, 2025-2035

9.5.7.3. Brazil Market Revenue, By Immunization Type, 2025-2035

9.5.7.4. Brazil Market Revenue, By Route of Administration, 2025-2035

9.5.7.5. Brazil Market Revenue, By End-user, 2025-2035

9.5.8. Argentina

9.5.8.1. Argentina Market Revenue, By Vaccine Type, 2025-2035

9.5.8.2. Argentina Market Revenue, By Vaccine Composition, 2025-2035

9.5.8.3. Argentina Market Revenue, By Immunization Type, 2025-2035

9.5.8.4. Argentina Market Revenue, By Route of Administration, 2025-2035

9.5.8.5. Argentina Market Revenue, By End-user, 2025-2035

9.5.9. Mexico

9.5.9.1. Mexico Market Revenue, By Vaccine Type, 2025-2035

9.5.9.2. Mexico Market Revenue, By Vaccine Composition, 2025-2035

9.5.9.3. Mexico Market Revenue, By Immunization Type, 2025-2035

9.5.9.4. Mexico Market Revenue, By Route of Administration, 2025-2035

9.5.9.5. Mexico Market Revenue, By End-user, 2025-2035

9.5.10. Rest of Latin America

9.5.10.1. Rest of Latin America Market Revenue, By Vaccine Type, 2025-2035

9.5.10.2. Rest of Latin America Revenue, By Vaccine Composition, 2025-2035

9.5.10.3. Rest of Latin America Market Revenue, By Immunization Type, 2025-2035

9.5.10.4. Rest of Latin America Market Revenue, By Route of Administration, 2025-2035

9.5.10.5. Rest of Latin America Market Revenue, By End-user, 2025-2035

9.6. MEA

9.6.1. MEA Market Revenue, By Country, 2025-2035 (USD Billion)

9.6.2. MEA Market Revenue, By Vaccine Type, 2025-2035

9.6.3. MEA Market Revenue, By Vaccine Composition, 2025-2035

9.6.4. MEA Market Revenue, By Immunization Type, 2025-2035

9.6.5. MEA Market Revenue, By Route of Administration, 2025-2035

9.6.6. MEA Market Revenue, By End-user, 2025-2035

9.6.7. GCC Countries

9.6.7.1. GCC Countries Market Revenue, By Vaccine Type, 2025-2035

9.6.7.2. GCC Countries Market Revenue, By Vaccine Composition, 2025-2035

9.6.7.3. GCC Countries Market Revenue, By Immunization Type, 2025-2035

9.6.7.4. GCC Countries Market Revenue, By Route of Administration, 2025-2035

9.6.7.5. GCC Countries Market Revenue, By End-user, 2025-2035

9.6.8. South Africa

9.6.8.1. South Africa Market Revenue, By Vaccine Type, 2025-2035

9.6.8.2. South Africa Market Revenue, By Vaccine Composition, 2025-2035

9.6.8.3. South Africa Market Revenue, By Immunization Type, 2025-2035

9.6.8.4. South Africa Market Revenue, By Route of Administration, 2025-2035

9.6.8.5. South Africa Market Revenue, By End-user, 2025-2035

9.6.9. Rest of Middle-East & Africa

9.6.9.1. Rest of Middle-East & Africa Market Revenue, By Vaccine Type, 2025-2035

9.6.9.2. Rest of Middle-East & Africa Market Revenue, By Vaccine Composition, 2025-2035

9.6.9.3. Rest of Middle-East & Africa Market Revenue, By Immunization Type, 2025-2035

9.6.9.4. Rest of Middle-East & Africa Market Revenue, By Route of Administration, 2025-2035

9.6.9.5. Rest of Middle-East & Africa Market Revenue, By End-user, 2025-2035

10. Company Profile

10.1. GlaxoSmithKline (GSK)

10.1.1. Business Overview

10.1.2. Financial Performance

10.1.3. Product/Service Offerings

10.1.4. Strategies & recent developments

10.1.5. SWOT Analysis

10.2. Merck & Co., Inc.

10.2.1. Business Overview

10.2.2. Financial Performance

10.2.3. Product/Service Offerings

10.2.4. Strategies & recent developments

10.2.5. SWOT Analysis

10.3. Pfizer Inc.

10.3.1. Business Overview

10.3.2. Financial Performance

10.3.3. Product/Service Offerings

10.3.4. Strategies & recent developments

10.3.5. SWOT Analysis

10.4. Moderna Inc.

10.4.1. Business Overview

10.4.2. Financial Performance

10.4.3. Product/Service Offerings

10.4.4. Strategies & recent developments

10.4.5. SWOT Analysis

10.5. Dynavax Technologies

10.5.1. Business Overview

10.5.2. Financial Performance

10.5.3. Product/Service Offerings

10.5.4. Strategies & recent developments

10.5.5. SWOT Analysis

10.6. Curevo Inc.

10.6.1. Business Overview

10.6.2. Financial Performance

10.6.3. Product/Service Offerings

10.6.4. Strategies & recent developments

10.6.5. SWOT Analysis

10.7. GeneOne Life Science

10.7.1. Business Overview

10.7.2. Financial Performance

10.7.3. Product/Service Offerings

10.7.4. Strategies & recent developments

10.7.5. SWOT Analysis

10.8. Jiangsu Recbio Technology Co., Ltd.

10.8.1. Business Overview

10.8.2. Financial Performance

10.8.3. Product/Service Offerings

10.8.4. Strategies & recent developments

10.8.5. SWOT Analysis

10.9. SK bioscience

10.9.1. Business Overview

10.9.2. Financial Performance

10.9.3. Product/Service Offerings

10.9.4. Strategies & recent developments

10.9.5. SWOT Analysis

10.10. CanSinoBIO

10.10.1. Business Overview

10.10.2. Financial Performance

10.10.3. Product/Service Offerings

10.10.4. Strategies & recent developments

10.10.5. SWOT Analysis

10.11. Changchun BCHT Biotechnology Co.

10.11.1. Business Overview

10.11.2. Financial Performance

10.11.3. Product/Service Offerings

10.11.4. Strategies & recent developments

10.11.5. SWOT Analysis

10.12. Vaccitech

10.12.1. Business Overview

10.12.2. Financial Performance

10.12.3. Product/Service Offerings

10.12.4. Strategies & recent developments

10.12.5. SWOT Analysis

10.13. Valneva SE

10.13.1. Business Overview

10.13.2. Financial Performance

10.13.3. Product/Service Offerings

10.13.4. Strategies & recent developments

10.13.5. SWOT Analysis

10.14. Bavarian Nordic

10.14.1. Business Overview

10.14.2. Financial Performance

10.14.3. Product/Service Offerings

10.14.4. Strategies & recent developments

10.14.5. SWOT Analysis

10.15. Johnson & Johnson

10.15.1. Business Overview

10.15.2. Financial Performance

10.15.3. Product/Service Offerings

10.15.4. Strategies & recent developments

10.15.5. SWOT Analysis